Annex 22 marks a paradigm shift in pharmaceutical manufacturing, not only because it closes the longstanding “AI grey zone” ...

Large-language models are excellent for general-use AI systems, but they don’t understand pharmaceutical companies’ ...

AI is remaking health care – and that includes gene-based precision medicine, among other types of rapid advances in treatment. The growing field of GenAI, or genetic AI, uses advanced algorithms ...

Trust is often a major barrier to companies integrating AI tools. Learn how better data governance can improve confidence.

Pharma marketing is shifting from a product-centered approach to one driven by data and engagement, according to Kamya Elawadhi, chief client officer at Doceree. In an interview with Fierce Pharma ...

The volume of raw data collected during clinical research is ever-growing—modern clinical trials "generate an average of 3.6 million data points" from regular site visits, labs, procedures, ...

After widespread AI experimentation in 2024, companies will face pressure to show real returns on their AI investments in 2025. This will drive adoption of vertical AI solutions that are purpose-built ...

aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise ...

Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found. The ...

Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 ...